Drug Profile
LT V11
Alternative Names: Hepatitis B virus TCR T-cell therapy - Lion TCR; LT V11Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Lion TCR
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Hepatitis-B in Singapore (Parenteral)
- 02 Feb 2022 Preclinical development ongoing in Hepatitis B in Singapore (Parenteral) (Lion TCR pipeline, August 2017)
- 02 Feb 2022 Lion TCR plans a phase I trial for Hepatitis-B in Singapore (Lion TCR pipeline, February 2022)